Understanding how chromatin and immune responses affect tumor growth in lung and pancreatic cancers
Official title: Chromatin and immune regulation of tumor growth and progression
Funded at Whitehead Institute for Biomedical Res · NIH-11162741 · Data updated 2026-11-12
This study is looking at how certain changes in cancer cells and the immune system affect late-stage lung and pancreatic cancers, with the hope of finding new ways to treat these aggressive cancers and improve outcomes for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Whitehead Institute for Biomedical Res NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $103,497 |
| NIH project number | 4K00CA284289-02 |
| Project ID | NIH-11162741 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with late-stage lung or pancreatic ductal adenocarcinomas.
✕Less likely to help
Patients with early-stage cancers or other types of tumors may not receive direct benefits from this research.
What this research studies
This research investigates the complex characteristics of late-stage lung and pancreatic cancers, which are often diagnosed when they are most aggressive. The focus is on understanding how changes in chromatin state and immune responses contribute to tumor heterogeneity and progression. By studying a specific tumor suppressor gene, STAG2, the research aims to uncover the biological processes that drive tumor development and how these mechanisms can be targeted for better treatment outcomes. Patients may benefit from insights that could lead to new therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve outcomes for patients with late-stage lung and pancreatic cancers.
How similar studies have gone: Other research has shown promise in understanding tumor heterogeneity and immune regulation, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Whitehead Institute for Biomedical Res
Cambridge, United States Active
Researchers
- Principal investigator: Ashkin, Emily Lorin — Whitehead Institute for Biomedical Res
- Study coordinator: Ashkin, Emily Lorin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.